OKYO Pharma
OKYO
7 hedge funds and large institutions have $176K invested in OKYO Pharma in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
1,187% more capital invested
Capital invested by funds: $13.7K → $176K (+$162K)
600% more funds holding
Funds holding: 1 → 7 (+6)
0.29% more ownership
Funds ownership: 0.05% → 0.34% (+0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$42K |
| 2 |
Renaissance Technologies
New York
|
+$27.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$26.8K |
| 4 |
Morgan Stanley
New York
|
+$23.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.3K |
Top Sellers
OKYO Hedge Fund Activity: Q3 2023 in Review
7 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q3 2023, worth a combined $176K — up 1,187% from $13.7K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new OKYO positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $42K.
- 7 institutional investors held OKYO Pharma (OKYO) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $176K of OKYO Pharma stock for Q3 2023, up 1,187% quarter-over-quarter.
- 6 funds opened new OKYO Pharma positions in Q3 2023 and 0 closed out, a net change of +6 holders.
- The largest OKYO Pharma buyer in Q3 2023 was Barclays, an estimated $42K added.
Based on aggregated 13F filings for Q3 2023.